The immune mechanisms of abscopal effect in radiation therapy

Current Problems in Cancer

Volumn 40, Issue 1, 2016, Pages 10-24

  Grass, G Daniel ^a   Krishna, Niveditha ^a   Kim, Sungjune ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CANCER VACCINE; TUMOR ANTIGEN;

ABSCOPAL EFFECT; ANTIGEN PRESENTING CELL; ARTICLE; CANCER RADIOTHERAPY; CYTOKINE PRODUCTION; DNA DAMAGE; ENDOPLASMIC RETICULUM STRESS; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; THERAPY EFFECT; TUMOR CELL DESTRUCTION; BYSTANDER EFFECT; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASM METASTASIS; NEOPLASMS; PROCEDURES;

ANTIGENS, NEOPLASM; BYSTANDER EFFECT; CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84961175492     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2015.10.003     Document Type: Article

References (137)

1. Siva S., MacManus M.P., Martin R.F., Martin O.A. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett 2015, 356:82-90.
2. Vatner R.E., Cooper B.T., Vanpouille-Box C., Demaria S., Formenti S.C. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol 2014, 4(325).
3. Eriksson D., Stigbrand T. Radiation-induced cell death mechanisms. Tumor Biol 2010, 31(4):363-372.
4. Kroemer G., Galluzzi L., Kepp O., Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31:51-72.
5. Garg A., Dudek A., Agostinis P. Cancer immunogenicity, danger signals, and DAMPS: what, when, and how?. Biofactors 2013, 39(4):355-367.
6. Bezu L., Gomes-da-Silva L.C., Dewitte H., et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol 2015, 6.
7. Stone H.B., Peters L.J., Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst 1979, 63(5):1229-1235.
8. Jurin M., Suit H.D. In vivo and in vitro studies of the influence of the immune status of C3Hf/Bu mice on the effectiveness of local irradiation of a methylcholanthrene-induced fibrosarcoma. Cancer Res 1972, 32(10):2201-2211.
9. de la Cruz-Merino L., Illescas-Vacas A., Grueso-Lopez A., Barco-Sanchez A., Miguez-Sanchez C. Radiation for awakening the dormant immune system, a promising challenge to be explored. Front Oncol 2014, 5(102).
10. Hiniker S.M., Chen D.S., Reddy S., et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 2012, 5(6):404-407.
11. Postow M.A., Callahan M.K., Barker C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931.
12. Golden E.B., Demaria S., Schiff P.B., Chachoua A., Formenti S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013, 1(6):365-372.
13. Schaue D., McBride W.H. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol 2015, 12:527-540.
14. Rodel F., Frey B., Multhoff G., Gaipl U.S. Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett 2015, 356(1):105-113.
15. Mole R.H. Whole body irradiation; radiobiology or medicine?. Br J Radiol 1953, 26(305):234-241.
16. Barcellos-Hoff M.H., Park C., Wright E.G. Radiation and the microenvironment-tumorigenesis and therapy. Nat Rev Cancer 2005, 5(11):867-875.
17. Prestwich R.J., Errington F., Hatfield P., et al. The immune system-is it relevant to cancer development, progression and treatment?. Clin Oncol 2008, 20(2):101-112.
18. Sanmamed M.F., Pastor F., Rodriguez A., et al. Agonists of Co-stimulation in cancer immunotherapy directed against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol 2015, 42(4):640-655.
19. Mittal D., Gubin M.M., Schreiber R.D., Smyth M.J. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014, 27:16-25.
20. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
21. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
22. Burkholder B., Huang R.-Y., Burgess R., et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 2014, 1845(2):182-201.
23. Desai S., Kumar A., Laskar S., Pandey B.N. Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells. Cytokine 2013, 61(1):54-62.
24. Calveley V.L., Khan M.A., Yeung I.W.T., Vandyk J., Hill R.P. Partial volume rat lung irradiation: temporal fluctuations of in-field and out-of-field DNA damage and inflammatory cytokines following irradiation. Int J Radiat Oncol Biol Phys 2005, 81(12):887-899.
25. Haikerwal S., Hagekyriakou J., MacManus M.P., Martin O.A., Haynes N.M. Building immunity to cancer with radiation therapy. Cancer Lett 2015, 368(2):198-208.
26. Kovacs C.J., Daly B.M., Evans M.J., et al. Cyokine profiles in patients receiving wide-field + prostate boost radiotherapy (xRT) for adenocarcinoma of the prostate. Cytokine 2003, 23(6):151-163.
27. Akmansu M., Unsal D., Bora H., Elberg S. Influence of locoregional radiation treatment on tumor necrosis factor-α and interleukin-6 in the serum of patients with head and neck cancer. Cytokine 2005, 31(1):41-45.
28. Sridharan V., Schoenfeld J.D. Immune effects of targeted radiation therapy for cancer. Discov Med 2015, 19(104):219-228.
29. Du S., Barcellos-Hoff M.H. Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas. Semin Radiat Oncol 2013, 23(4):242-251.
30. Kim J.H., Jenrow K.A., Brown S.L. Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials. Radiat Oncol J 2014, 32(3):103-115.
31. Hojo S., Koizumi K., Tsuneyama K., et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007, 67(10):4725-4731.
32. Siva S., MacManus M.P., Kron T., et al. A pattern of early radiation-induced inflammatory cytokine expression is associated with lung toxicity in patients with non-small cell lung cancer. PLoS One 2014, 9(10):e109560.
33. Rello-Varona S., Herrero-Martin D., Lopez-Alemany R., Munoz-Pinedo C., Tirado O.M. (Not) All (dead) things share the same breath: identification of cell death mechanisms in anticancer therapy. Cancer Res 2015, 75(6):913-917.
34. O'Brien M.A., Power D.G., Clover A., Bird B., Soden D.M., Forde P.F. Local tumour ablative therapies: opportunities for maximising immune engagement and activation. Biochim Biophys Acta 2014, 1846:510-523.
35. Wiersma V.R., Michalak M., Abdullah T.M., Bremer E., Eggleton P. Mechanisms of translocation of ER chaperones to the cell surface and immunomodulatory roles in cancer and autoimmunity. Front Oncol 2015, 5(7).
36. Kepp O., Semeraro M., Bravo-San Pedro J.M., et al. eIF2α phosphorylation as a biomarker of immunogenic cell death. Semin Cancer Biol 2015.
37. Ellgaard L., Helenius A. Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 2003, 4(3):181-191.
38. Hetz C., Chevet E., Oakes S.A. Proteostasis control by the unfolded protein response. Nat Cell Biol 2015, 17(7):829-838.
39. Golden E.B., Frances D., Pellicciotta I., Demaria S., Barcellos-Hoff M.H., Formenti S.C. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 2014, 3:e28518.
40. Gameiro S.R., Jammeh M.L., Wattenberg M.M., Tsang K.Y., Ferrone S., Hodge J.W. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 2013, 5(2):403-416.
41. Obeid M., Tesniere A., Ghiringhelli F., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13(1):54-61.
42. Raghavan M., Wijeyesakere S.J., Peters L.R., Del Cid N. Calreticulin in the immune system: ins and outs. Trends Immunol 2013, 34(1):13-21.
43. Kepp O., Galluzzi L., Giordanetto F., et al. Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell Cycle 2009, 8(23):3971-3977.
44. Panaretakis T., Joza N., Modjtahedi N., et al. The co-translation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008, 15:1499-1509.
45. Obeid M. ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin. J Immunol 2008, 181(4):2533-2543.
46. Peters L.R., Raghavan M. Endoplasmic reticulum calcium depletion impacts chaperone secretion. Innate immunity, and phagocytic uptake of cells. J Immunol 2011, 187(2):919-931.
47. Garg A., Krysko D.V., Vandenabeele P., Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol 2011, 61(2):215-221.
48. Panaretakis T., Kepp O., Brockmeier U., et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009, 28(5):453-613.
49. Vandivier R.W., Ogden C.A., Fadok V.A., et al. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol 2002, 169(7):3978-3986.
50. Baruah P., Dumitriu I.E., Malik T.H., et al. C1q enhances IFN-γ production by antigen-specific T cells via CD40 costimulatory pathway on dendritic cells. Blood 2009, 113(15):3485-3493.
51. Chao M.P., Jaiswal S., Weissman-Tsukamoto R., et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010, 2(63):63ra94.
52. Gardai S.J., McPhillips K.A., Frasch S.C., et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123(2):321-334.
53. de Bruyn M., Wiersma V.R., Helfrich W., Eggleton P., Bremer E. The ever-expanding immunomodulatory role of calreticulin in cancer immunity. Front Oncol 2015, 5(35).
54. Sheng W., Chen C., Dong M., Dong Q., Li F. Overexpression of calreticulin contributes to the development and progression of pancreatic cancer. J Cell Physiol 2014, 229(7):887-897.
55. Kabbage M., Trimeche M., Bergaoui S., et al. Calreticulin expression in infiltrating ductal breast carcinomas: relationships with disease progression and humoral immune response. Tumor Biol 2013, 34(2):1177-1188.
56. Du X.-L., Yang H., Liu S.-G., et al. Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma. Oncogene 2009, 28(42):3714-3722.
57. Chen C.-N., Chang C.-C., Su T.-E., et al. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol 2009, 16(2):524-533.
58. Diener K., Al-Dasooqi N., Lousberg E.L., Hayball J.D. The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer. Immunol Cell Biol 2013, 91(7):443-450.
59. Apetoh L., Ghiringhelli F., Tesniere A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13(9):1050-1059.
60. Sims G.P., Rowe D.C., Rietdijk S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in Inflammation and Cancer. Ann Rev Immunol 2010, 28:367-388.
61. Suzuki Y., Mimura K., Yoshimoto Y., et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 2012, 72(16):3967-3976.
62. Kostova N., Zlateva S., Ugrinova I., Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 2010, 337(1-2):251-258.
63. Michaud M., Martins I., Sukkurwala A.Q., et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334(6062):1573-1577.
64. Ghiringhelli F., Apetoh L., Tesniere A., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat Med 2009, 15(10):1170-1180.
65. Lazarowski E., Boucher R.C., Harden T.K. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol 2003, 64(4):785-795.
66. Stagg J., Smyth M.J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010, 29(39):5346-5358.
67. Sistigu A., Yamazaki T., Vacchelli E., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014, 20(11):1301-1309.
68. Lianos G.D., Alexiou G.A., Mangano A., et al. The role of heat shock proteins in cancer. Cancer Lett 2015, 360(2):114-118.
69. Srivastava P.K., Udono H., Blachere N.E., Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994, 39(2):93-98.
70. Land W.G. Role of heat shock protein 70 in innate alloimmunity. Front Immunol 2012, 2(89).
71. Leone P., Shin E.-C., Perosa F., et al. Antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst 2013, 105(16):1172-1187.
72. Reits E.A., Hodge J.W., Herberts C.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006, 203(5):1259-1271.
73. Kim J.-Y., Son Y.-O., Park S.-W., et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 2006, 38(5):474-484.
74. Gasser S., Orsulic S., Brown E.J., Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436(7054):1186-1190.
75. Kim S., Ramakrishnan R., Lavilla-Alonso S., et al. Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother 2014, 63(10):1009-1021.
76. Ramakrishnan R., Assudani D., Nagaraj S., et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010, 120(4):1111-1124.
77. Multhoff G., Pockley A.G., Schmid T.E., Schilling D. The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation. Cancer Lett 2015.
78. Luce A., Courtin A., Levalois C., et al. Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells. Carcinogenesis 2009, 30(3):432-439.
79. Golden E.B., Pellicciotta I., Demaria S., Barcellos-Hoff M.H., Formenti S.C. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2012, 2(88).
80. Galluzzi L., Kepp O., Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology 2013, 2(10):e26536.
81. Obeid M., Panaretakis T., Joza N., et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007, 14(10):1848-1850.
82. Chakravarty P.K., Alfieri A., Thomas E.K., et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 1999, 59(24):6028-6032.
83. Demaria S., Ng B., Devitt M.L., et al. Ionizing radiation inhibition of distant untreated tumors (Abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004, 58(3):862-870.
84. Camphausen K., Moses M.A., Menard C., et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res 2003, 63(8):1990-1993.
85. Johnstone C.N., Smith Y.E., Cao Y., et al. Functional and molecular characterisation of E0771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Model Mech 2015, 8(3):237-251.
86. Reynders K., Illidge T., Siva S., Chang J.Y., De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev 2015, 41(6):503-510.
87. Demaria S., Formenti S.C. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol 2012, 2(95).
88. Burnette B.C., Liang H., Lee Y., et al. The efficacy of radiotherapy relies upon induction of type I inteferon-dependent innate and adpative immunity. Cancer Res 2011, 71(7):2488-2496.
89. Wu L., Wu M.O., de la Maza L., et al. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model. Oncotarget 2015, 6(14):12468-12480.
90. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015, 348(6230):56-61.
91. Peggs K.S., Quezada S.A., Allison J.P. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008, 224(1):141-165.
92. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
93. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12(4):252-264.
94. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2):122-133.
95. Weber J.S., Kudchadkar R.R., Yu B., et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013, 31(34):4311-4318.
96. Weber J.S., D'Angelo S.P., Minor D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015, 16(4):375-384.
97. Postow M.A., Chesney J., Pavlick A.C., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015, 372(21):2006-2017.
98. Yaqub F. Nivolumab for squamous-cell non-small-cell lung cancer. Lancet Oncol 2015, 16(7):e319.
99. Rajan A., Gulley J.L. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 2014, 3(6):403-405.
100. Gettinger S.N., Horn L., Gandhi L., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015, 33(18):2004-2012.
101. Ansell S.M., Lesokhin A.M., Borrello I., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015, 372(4):311-319.
102. Trautmann L., Janbazian L., Chomont N., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006, 12(10):1198-1202.
103. Day C.L., Kaufmann D.E., Kiepiela P., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443(7109):350-354.
104. Demaria S., Kawashima N., Yang A.M., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005, 11(2 pt 1):728-734.
105. Dewan M.Z., Galloway A.E., Kawashima N., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clini Cancer Res 2009, 15(17):5379-5388.
106. Park S.S., Dong H., Liu X., et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 2015, 3(6):610-619.
107. Deng L., Liang H., Burnette B.C., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014, 124(2):687-695.
108. Dovedi S.J., Adlard A.L., Lipowska-Bhalla G., et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014, 74(19):5458-5468.
109. Ma S.Y., Song H., Park J.-H., et al. Addition of anti-neu antibody to local irradiation can improve tumor-bearing BALB/c mouse survival through immune-mediated mechanisms. Radiat Res 2015, 183(3):271-280.
110. Park S., Jiang Z., Mortenson E.D., et al. The therapeutic effect of Anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010, 18(2):160-170.
111. Hanna G.G., Coyle V.M., Prise K.M. Immune modulation in advanced radiotherapies: targeting out-of-field effects. Cancer Lett 2015, 368(2):246-251.
112. Kwon E.D., Drake C.G., Scher H.I., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014, 15(7):700-712.
113. Twyman-Saint Victor C., Rech A., Maity A., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520(7547):373-377.
114. Ruocco M.G., Pilones K.A., Kawashima N., et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest 2012, 122(10):3718-3730.
115. Weng N.-p. Aging of the immune system: how much can the adaptive immune system adapt?. Immunity 2006, 24(5):495-499.
116. Yuan J., Adamow M., Ginsberg B.A., et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. PNAS 2011, 108(40):16723-16728.
117. Ohba K., Omagari K., Nakamura T., et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 1998, 43(4):575-577.
118. Pilones K.A., Kawashima N., Yang A.M., Babb J.S., Formenti S.C., Demaria S. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res 2009, 15(2):597-606.
119. Schreiber T.H., Raez L., Jd Rosenblatt, Podack E.R. Tumor immunogenicity and responsiveness to cancer vaccine therapy; the state of the art. Semin Immunol 2010, 22(3):105-112.
120. Kumar T., Patel N., Talwar A. Spontaneous regression of thoracic malignancies. Respir Med 2010, 104(10):1543-1550.
121. Brahmer J., Reckamp K.L., Baas P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015, 373(2):123-135.
122. Almendro V., Kim H.J., Cheng Y.-K., et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 2014, 74(5):1338-1348.
123. Jamal-Hanjani M., Quezada S.A., Larkin J., Swanton C. Translational implications of tumor heterogeneity. Clin Cancer Res 2015, 21(6):1258-1266.
124. Modore J., Vilain R.E., Menzies A.M., et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials Pigment Cell. Melanoma Res 2015, 28(3):245-253.
125. Larkin J., Chiarion-Sileni V., Gonzalez R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 373(1):23-34.
126. Robert C., Long G.V., Brady B., et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015, 372(4):320-330.
127. Mothersill C., Seymour C. Radiation-induced bystander effects: are they good, bad or both?. Med Confl Surviv 2005, 21(3):101-110.
128. Lee Y., Auh S.L., Wang Y., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114(3):589-595.
129. Merrick A., Errington F., Milward K., et al. Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br J Cancer 2005, 92(8):1450-1458.
130. Manda K., Glasow A., Paape D., Hildebrandt G. Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic cells and T cells. Front Oncol 2012, 2(102).
131. Garnett C.T., Palena C., Chakarborty M., Tsang K.Y., Schlom J., Hodge J.W. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced cell killing by cytotoxic T lymphocytes. Cancer Res 2004, 64(21):7985-7994.
132. Golden E.B., Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol 2015, 25:11-17.
133. Zahidunnabi M., Galloway A.E., Kawashima N., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15(17):5379-5388.
134. Schaue D., Ratikan J.A., Iwamoto K., McBride W.H. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2012, 83(4):1306-1310.
135. Golden E.B., Formenti S.C. Radiation therapy and immunotherapy: growing pains. Int J Radiat Oncol Biol Phys 2014, 91(2):252-254.
136. Huang J., Wang Q.J., Yang S., et al. Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro. J Immunother 2011, 34(4):327-335.
137. Yu E.Y., Gabrilovich D.I. Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 2001, 94(6):825-833.